The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as AzaSite, Zymaxid, Moxeza, and Vigamox, are set to lose their marketing exclusivity very soon.

The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.

Download free exclusive Brochure of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12323

Rising Prevalence of MDROs Creates Serious Challenge for Market’s Growth

Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.

Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.

Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones

Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.

The market’s opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.

Global strategic Business report:
http://www.transparencymarketresearch.com/us-bacterial-conjunctivitis-drugs-market.html

Imminent Patent Expiries to Hurt Leading Players Severely

Valeant Pharmaceuticals Int. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Com. Plc., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis Plc. are leading the market for bacterial conjunctivitis drugs in the U.S. The imminent patent expiries is likely to hurt the business of these players significantly in the near future. However, the rising prevalence of bacterial infection in eyes and the increasing susceptibility to infection among individuals of various age groups may provide rewarding opportunities to participants over the next few years.

Players are recommended to focus on developing herbal medicines for the treatment of bacterial conjunctivitis, as the consumer preference is shifting from pharmacological medicines to herbal treatment regimens.